Mutations in fbiD (Rv2983) as a Novel Determinant of Resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis.

doi:10.1128/AAC.01948-20

Article

Mutations in fbiD (Rv2983) as a Novel Determinant of Resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis.

Antimicrobial agents and chemotherapy - 16 Dec 2020

Rifat Dalin, Li Si-Yang, Ioerger Thomas, Shah Keshav, Lanoix Jean-Philippe, Lee Jin, Bashiri Ghader, Sacchettini James, Nuermberger Eric

Abstract excerpt

The nitroimidazole prodrugs delamanid and pretomanid comprise one of only two new antimicrobial classes approved to treat tuberculosis (TB) in 50 years. Prior in vitro studies suggest a relatively low barrier to nitroimidazole resistance in Mycobacterium tuberculosis, but clinical evidence is lim...

Topics

Animals
Antitubercular Agents
Mice
Mutation
Mycobacterium tuberculosis
Nitroimidazoles
Oxazoles

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.